Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533567 | 0.82 | FAAH (0.41) | ALDH1A1HTR7MEN1KMT2AALOX5 | |
| SCHEMBL3529011 | 0.81 | NAPRT (0.41) | ALDH1A1MEN1KMT2AALOX5GAA | |
| SCHEMBL3531384 | 0.80 | NAPRT (0.57) | ALDH1A1HTR7MEN1KMT2ACYP1A2 | |
| SCHEMBL29238912 | 0.79 | NAPRT (0.61) | ALDH1A1NOTUMARMEN1KMT2A | |
| SCHEMBL3531717 | 0.77 | ALDH1A1 (0.45) | CYP17A1ALDH1A1NOTUMHTR7AR | |
| SCHEMBL3531196 | 0.76 | ALDH1A1 (0.44) | CYP17A1ALDH1A1NOTUMHTR7AR | |
| SCHEMBL3533292 | 0.75 | HSD11B1 (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL3533603 | 0.75 | NAPRT (0.54) | ALDH1A1HTR7KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL3530770 | 0.75 | NAPRT (0.39) | ALDH1A1HTR7MEN1KMT2AGAA | |
| SCHEMBL3535467 | 0.71 | MEN1 (0.41) | ALDH1A1NOTUMMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652057-B2 | Pyrazolones as 11b-HSD1 inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1924562-A2 | PYRAZOLONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025880-A2 | PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | HSD11B1, HSD17B1, HSD17B7 | CYP17A1 16/4885ALDH1A1 105/4885NOTUM 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.